MLN4924: Targeting Neddylation Pathways for Solid Tumor Research

Introduction

The ubiquitin-proteasome system and its regulatory modifications, such as neddylation, are central to cellular homeostasis and cancer pathogenesis. Neddylation, the covalent attachment of NEDD8 to substrate proteins, predominantly cullins, modulates the activity of cullin-RING ligases (CRLs), which in turn orchestrate the ubiquitination and proteasomal degradation of key cell cycle regulators and proto-oncogenes. Dysregulation of neddylation and CRL activity is frequently observed in a variety of cancers, making components of the neddylation pathway attractive targets for anti-cancer therapeutic development. MLN4924 (also known as pevonedistat) is a potent and selective inhibitor of the NEDD8-activating enzyme (NAE), which has emerged as a valuable small molecule tool for dissecting the biological roles of neddylation in solid tumor models and beyond.

Mechanism of Action: MLN4924 as a Selective NAE Inhibitor for Cancer Research

MLN4924 (SKU: B1036) exerts its function by competitively binding the nucleotide-binding site of the NEDD8-activating enzyme, thereby preventing the activation of NEDD8 and subsequent transfer to E2 conjugating enzymes. With an IC₅₀ of 4 nM, MLN4924 displays remarkable specificity towards NAE, showing substantially higher IC₅₀ values for related enzymes such as UAE, SAE, UBA6, and ATG7. This selectivity is essential for elucidating the functional consequences of neddylation pathway inhibition without significant off-target effects. By blocking NEDD8 conjugation, MLN4924 impedes the formation of Ubc12–NEDD8 thioester and NEDD8–cullin conjugates, culminating in the inactivation of CRLs. The downstream consequence is the stabilization and accumulation of CRL substrates, such as the replication licensing factor CDT1, which disrupts normal cell cycle progression and can induce apoptosis in cancer cells.

Neddylation Pathway Inhibition: Implications for Cancer Biology Research

Recent research has underscored the importance of neddylation in regulating not only CRLs but also non-cullin substrates, thereby expanding the scope of neddylation’s impact on oncogenic signaling. For example, the study by Zhang et al. (EMBO Journal, 2025) identified RHEB, a small GTPase and direct activator of mechanistic target of rapamycin complex 1 (mTORC1), as a substrate for neddylation via the UBE2F-SAG axis. Neddylation of RHEB enhances its lysosomal localization and GTP-binding affinity, thereby promoting mTORC1 activation—a pathway frequently upregulated in hepatocellular carcinoma and other solid tumors. Inhibition of neddylation via genetic or pharmacological means, such as with MLN4924, disrupts this modification and attenuates mTORC1-driven tumorigenesis, providing a mechanistic rationale for targeting neddylation in cancer biology research.

MLN4924 in Solid Tumor Models: Evidence from Xenograft Studies

Preclinical studies have demonstrated the efficacy of MLN4924 in inhibiting tumor growth across a range of xenograft models, including HCT-116 colon carcinoma, H522 lung tumor, and Calu-6 lung carcinoma. In these models, subcutaneous administration of MLN4924 at doses of 30 mg/kg and 60 mg/kg led to significant tumor growth inhibition with minimal toxicity, as evidenced by the preservation of body weight. The dose-dependent inhibition of NAE activity by MLN4924 observed in HCT-116 cells translates into impaired CRL-mediated ubiquitination and accumulation of substrates relevant to cell cycle regulation. Collectively, these findings support the use of MLN4924 as a research tool for dissecting the neddylation pathway’s role in tumor progression and for evaluating novel therapeutic interventions targeting protein homeostasis in solid tumor models.

Expanding the Landscape: Neddylation Beyond Cullin-RING Ligases

While the majority of neddylation research has historically focused on cullins and CRL regulation, emerging evidence points to non-cullin targets as key mediators of neddylation-dependent oncogenic signaling. The aforementioned study by Zhang et al. (EMBO Journal, 2025) demonstrated that RHEB neddylation by the UBE2F-SAG axis is critical for full mTORC1 activation and liver tumorigenesis. Notably, Ube2f knockout in mouse liver attenuated mTORC1 activity, reduced tumor burden, and improved outcomes in models of PTEN-deficient hepatocellular carcinoma. These findings suggest that NAE inhibition by MLN4924 could exert anti-tumor effects not only by disrupting CRL substrate turnover, but also by modulating the stability and function of non-cullin proteins that drive oncogenesis. This expanded mechanistic insight underscores the versatility of MLN4924 as a selective NAE inhibitor for cancer research and highlights the need for deeper investigation into the full repertoire of neddylation substrates in malignancy.

Experimental Considerations: Biochemical Properties and Usage Guidance for MLN4924

MLN4924 is supplied as a solid compound with a molecular weight of 443.53, and is readily soluble at concentrations ≥22.18 mg/mL in DMSO and ≥42.2 mg/mL in ethanol, but is insoluble in water. For experimental applications, stock solutions should be prepared using DMSO or ethanol and stored at -20°C; solutions are recommended for short-term use to maintain compound integrity. In cellular assays, MLN4924 induces dose-dependent inhibition of NAE, and optimal concentrations should be empirically determined based on cell type and experimental endpoint. Its high selectivity profile allows for the dissection of neddylation-specific signaling events with minimal interference from ubiquitin or SUMO pathway inhibition. When employing MLN4924 in animal studies, appropriate dosing regimens and toxicity monitoring are crucial, given the compound’s potent biological activity and effects on cell cycle regulation.

Translational Potential: MLN4924 in Anti-Cancer Therapeutic Development

The robust inhibition of the neddylation pathway by MLN4924 has catalyzed interest in its therapeutic potential, particularly for the treatment of solid tumors characterized by CRL and mTORC1 pathway hyperactivation. As the neddylation axis is implicated in the regulation of oncogenic drivers, tumor suppressor stability, and cell cycle progression, MLN4924 offers a unique approach to targeting protein homeostasis in malignancy. While preclinical data support its efficacy in tumor growth inhibition, further studies are warranted to delineate optimal combination strategies, identify predictive biomarkers, and mitigate potential toxicities associated with global neddylation blockade. The findings by Zhang et al. (EMBO Journal, 2025) linking RHEB neddylation to mTORC1 activation further highlight the promise of NAE inhibitors in modulating critical nodes of oncogenic signaling and metabolic regulation in cancer.

Conclusion

MLN4924 has established itself as an indispensable small molecule for probing the intricacies of neddylation pathway inhibition, CRL-mediated ubiquitination, and cell cycle regulation in cancer biology research. Its potency, selectivity, and demonstrated efficacy in solid tumor models provide a strong foundation for both basic mechanistic studies and translational anti-cancer therapeutic development. Notably, the ability of MLN4924 to modulate both cullin and non-cullin neddylation substrates, as exemplified by recent discoveries in mTORC1 signaling, opens new avenues for research and intervention in malignancy. For further foundational information on MLN4924’s selectivity and preclinical utility, readers may consult the article MLN4924: Selective NAE Inhibitor Targeting Neddylation in.... This present article extends beyond the core mechanisms covered in that piece by integrating the latest insights into non-cullin neddylation, such as RHEB modification and its impact on mTORC1 activity, thereby providing a broader and more nuanced perspective on the role of neddylation pathway inhibition in cancer research.